|本期目录/Table of Contents|

[1]董笑影 综述,魏 蔚 审校. 沙利度胺治疗肺纤维化新进展[J].天津医科大学学报,2015,21(03):272-274.
点击复制

 沙利度胺治疗肺纤维化新进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
21卷
期数:
2015年03期
页码:
272-274
栏目:
综述
出版日期:
2015-05-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2015）03-0272-03
作者:
 董笑影 综述; 魏 蔚 审校
 （天津医科大学总医院风湿免疫科 ， 天津 300052）
Author(s):
-
关键词:
沙利度胺; 肺纤维化; 血管新生; 风湿病; 血管炎
Keywords:
-
分类号:
R593.2
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1]Vande Broek I, Jacobs P. Continuous treatment in multiple myeloma: The future[J]. Transfus Apher Sci, 2013,49(2):147

[2]Feng Y M, Feng C W, Chen S C. Unexpected remission of hepatocellular carcinoma(HCC)with lung metastasis to the combination therapy of Thalidomide and cyproheptadine:report of two cases and a preliminary HCC cell line study[J]. BMJ Case Rep, 2012,12(9):1136

[3]Lee S M, Hackshaw A. A potential new enriching trial design for selecting non-small-cell lung Cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a Thalidomide trial[J]. Cancer Med, 2013,2(3):360

[4]Liang C, Guo S, Yang L. Effects of all?trans retinoic acid on VEGF and HIF?1α expression in glioma cells under normoxia and hypoxia and its anti?angiogenic effect in an intracerebral glioma model[J]. Mol Med Rep, 2014,10(5):2713

[5]Zielonka T M. Angiogenesis in interstitial lung diseases[J]. Pneumonol Alergol Pol, 2009,77(1):52

[6]Lechtzin N, Hilliard M E, Horton M R. Validation of the cough Quality-of-Life questionnaire in patients with idiopathic pulmonary fibrosis[J]. Chest, 2013,143(6):1745

[7]Dredge K, Marriott J B, Todryk S M, et al. Protective antitumor immunity induced by a costimulatory Thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity[J]. J Immunol, 2002,168(10):4914

[8]Leiba M, Avigdor A. Bortezomib, Thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al[J]. Br J Haematol, 2014,24(4):131

[9]李冬，徐丽艳，常子娟，等. 沙利度胺对百草枯诱导小鼠急性肺损伤的干预[J]. 中华劳动卫生职业病杂志, 2013,31(3):178

[10]Buckstein R, Kerbel R, Cheung M, et al. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis[J]. Leuk Res, 2014,38(7):756

[11]Tan H, Chen H, Xu C, et al. Role of vascular endothelial growth factor in angiodysplasia: an interventional study with Thalidomide[J]. Gastroenterol Hepatol, 2012,27(6):1094

[12]Knobloch J, Jungck D, Koch A. Apoptosis induction by Thalidomide:critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis?[J]. Curr Mol Pharmacol, 2011,4(1):26

[13]Lee S M, Hackshaw A. A potential new enriching trial design for selecting non-small-cell lung Cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a Thalidomide trial[J]. Cancer Med, 2013,2(3):360

[14]Liu Y, He S, Ding Y, et al. The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung Cancer: a meta-analysis[J]. Contemp Oncol (Pozn), 2014,18(1):39

15.Zahran MA, Abdin YG, Osman AM.Synthesis and evaluation of thalidomide and phthalimide esters as antitumor agents[J]. Arch Pharm (Weinheim). 2014 ;347(9):642

[16]Lei W, Zhou K S, Li Y F. Application of lenalidomide in chronic lymphocytic leukemia[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2014,22(2):565

[17]Frankel H. Sharon VR,vleugels RA,rt al.lower-dose Thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity[J]. Int J Dermatol, 2013,52(11):1407

[18]Rigante D, La Torre F, Calcagno G A. Clinical response to Thalidomide and colchicine in two siblings with Behcet’s disease carrying a single mutated MEFV allele[J]. Rheumatol Int, 2012,32(6):1859

[19]Druhorton M R, Hallowell. Revisiting Thalidomide:fighting with caution against idiopathic pulmonary fibrosi[J]. Drugs Today (Barc), 2012,48(10):661

[20]Zhao L, Xiao K, Wang H, et al. Thalidomide has a therapeutic effect on interstitial lung fibrosis:evidence from in vitro and in vivo studies[J]. Clin Exp Immunol, 2009,157(2):310

[21]Tseng C M, Hsiao Y H, Su V Y. The suppression effects of Thalidomide on human lung fibroblasts:cell proliferation,vascular endothelial growth factor release,and collagen production[J]. Lung, 2013,191(4):361

[22]杨渭临，章琳，张王刚，等. 沙利度胺治疗老年肺间质纤维化38例分析[J]. 陕西医学杂志, 2011,40(1):91

相似文献/References:

[1]郭 艳,曹海龙,董文逍,等.空肠海绵状血管瘤致反复小肠出血1例[J].天津医科大学学报,2017,23(03):245.
[2]王硕,张军,严一杰,等.肺癌合并肺纤维化患者在肺癌根治术中手术风险的评估[J].天津医科大学学报,2018,24(02):156.
　WANG Shuo,ZHANG Jun,YAN Yi-jie,et al.Risk assessment of lung cancer combined with pulmonary fibrosis in lung cancer radical surgery[J].Journal of Tianjin Medical University,2018,24(03):156.
[3]徐雷倩,曹 洁.FSTL1促进间歇性低氧诱导的肺成纤维细胞活化[J].天津医科大学学报,2019,25(05):446.
　XU Lei-qian,CAO Jie.FSTL1 promotes intermittent hypoxia-induced lung fibroblast activation[J].Journal of Tianjin Medical University,2019,25(03):446.
[4]闫喆.主动循环呼吸技术对进展性纤维化性间质性肺病患者的治疗效果[J].天津医科大学学报,2022,28(04):414.
　YAN Zhe.Effect of active cycle of breathing technologies on patients with progressive fibrotic interstitial lung disease[J].Journal of Tianjin Medical University,2022,28(03):414.

备注/Memo

备注/Memo:
作者简介 董笑影（1972-），女，副主任医师，硕士，研究方向：风湿免疫专业；

通信作者：魏蔚，E-mail:tjweiwei2003@163.com。



更新日期/Last Update: 2015-05-27